Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis
- PMID: 2059756
Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis
Abstract
Intensive chemoradiotherapy conditioning regimens and acute graft-versus-host disease (GVHD) are both associated with significant morbidity and mortality after bone marrow transplantation. In this study, we investigated whether the conditioning regimen affected the development of acute GVHD. Thirty-four patients, four with severe aplastic anemia and 30 with a lymphohemopoietic malignancy, were prepared for transplantation either with cyclophosphamide (CY) alone, with CY combined with total body irradiation (TBI) or CY combined with etoposide and either TBI or busulfan. GVHD prophylaxis included methotrexate (MTX 10 mg/m2) given on days 1, 3 and 6, and daily cyclosporine (CSP) on days--1 through 180. The overall incidence of acute GVHD was 36% (15% for HLA identical, 87% for HLA non-identical recipients). However, when assessed by the severity of conditioning regimen-related toxicity, the incidence of GVHD grades II-IV (HLA identical; HLA non-identical) was 0% (0%; 0%), 37% (20%; 67%) and 50% (22%; 100%) for patients with mild, moderate and severe toxicity, respectively. Compliance with GVHD prophylaxis declined with increasing intensity and toxicity of the conditioning regimen. These data suggest that a regimen of three doses of MTX and daily CSP is as effective as four doses of MTX/CSP for GVHD prophylaxis in patients given HLA identical marrow grafts. However, GVHD regimen compliance and efficacy of GVHD prevention are inversely related to the intensity of the conditioning regimen.
Similar articles
-
Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.Bone Marrow Transplant. 1993 Nov;12(5):437-41. Bone Marrow Transplant. 1993. PMID: 8298553 Clinical Trial.
-
Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients.Bone Marrow Transplant. 1994 Jul;14(1):79-87. Bone Marrow Transplant. 1994. PMID: 7951124 Clinical Trial.
-
Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.Biol Blood Marrow Transplant. 2007 Jul;13(7):790-805. doi: 10.1016/j.bbmt.2007.03.002. Epub 2007 Apr 23. Biol Blood Marrow Transplant. 2007. PMID: 17580257
-
Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review.
-
Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.Clin Pharm. 1993 Oct;12(10):736-61. Clin Pharm. 1993. PMID: 8258255 Review.
Cited by
-
Clinical outcomes of patients receiving three versus four doses of methotrexate with concomitant antithymocyte globulin in match unrelated donor allogeneic stem cell transplant: A single-center experience.EJHaem. 2024 Apr 28;5(3):578-583. doi: 10.1002/jha2.909. eCollection 2024 Jun. EJHaem. 2024. PMID: 38895065 Free PMC article.
-
Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome.Int J Hematol. 2005 Jul;82(1):66-71. doi: 10.1532/IJH97.A30501. Int J Hematol. 2005. PMID: 16105763 Clinical Trial.
-
Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.Tissue Antigens. 2013 Apr;81(4):183-93. doi: 10.1111/tan.12090. Tissue Antigens. 2013. PMID: 23510414 Free PMC article. Review.
-
Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.J Clin Invest. 1999 Aug;104(4):459-67. doi: 10.1172/JCI6896. J Clin Invest. 1999. PMID: 10449438 Free PMC article.
-
Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.Blood. 2015 Jul 16;126(3):415-22. doi: 10.1182/blood-2015-04-642652. Epub 2015 Jun 1. Blood. 2015. PMID: 26031916 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Research Materials